Ashish Shah1, Abbas Fehmi, Thomas J Savides. 1. Division of Gastroenterology, Department of Medicine, University of California San Diego, La Jolla, CA, USA, shahar3682@gmail.com.
Abstract
BACKGROUND: Duodenal obstruction from pancreatic cancer historically occurs in 2-25 % of patients without surgery, but with new advances in chemotherapy and radiation therapy, the life expectancy of pancreatic cancer has increased. AIM: The aim of the study was to determine the rate of development of duodenal obstruction requiring intervention in patients with pancreatic head adenocarcinoma who do not undergo surgical resection, but receive modern chemoradiation. METHODS: It is a retrospective single center study. Inclusion criteria were patients with pancreatic cancer who underwent ERCP with metal biliary stent and then chemoradiation who subsequently developed symptomatic duodenal obstruction and underwent either metal duodenal stent placement or surgical duodenal bypass. RESULTS: Twenty-four of 63 patients (38 %, 95 % CI 26-50 %) with unresectable pancreatic cancer and biliary stents who received chemotherapy and/or radiation therapy developed duodenal obstruction. The average length of time from diagnosis of pancreatic adenocarcinoma to development of outlet obstruction was 11.4 ± 4.9 months (range 1.5-40 months). Average length of time from development of duodenal obstruction to death was 4.8 ± 2.1 months (range 0.5-60 months). Average survival time from diagnosis to death was 16.6 ± 5.6 months (range 4.5-58 months). CONCLUSION: Thirty-eight percent of patients with unresectable pancreatic head adenocarcinoma and metal biliary stents who receive chemotherapy and/or radiation therapy eventually develop symptomatic duodenal obstruction requiring duodenal stent or surgical bypass. This rate of duodenal obstruction is nearly twice that of previous reports using older oncologic therapy and will likely increase as patients survive longer with advances in medical therapy for pancreatic cancer.
BACKGROUND: Duodenal obstruction from pancreatic cancer historically occurs in 2-25 % of patients without surgery, but with new advances in chemotherapy and radiation therapy, the life expectancy of pancreatic cancer has increased. AIM: The aim of the study was to determine the rate of development of duodenal obstruction requiring intervention in patients with pancreatic head adenocarcinoma who do not undergo surgical resection, but receive modern chemoradiation. METHODS: It is a retrospective single center study. Inclusion criteria were patients with pancreatic cancer who underwent ERCP with metal biliary stent and then chemoradiation who subsequently developed symptomatic duodenal obstruction and underwent either metal duodenal stent placement or surgical duodenal bypass. RESULTS: Twenty-four of 63 patients (38 %, 95 % CI 26-50 %) with unresectable pancreatic cancer and biliary stents who received chemotherapy and/or radiation therapy developed duodenal obstruction. The average length of time from diagnosis of pancreatic adenocarcinoma to development of outlet obstruction was 11.4 ± 4.9 months (range 1.5-40 months). Average length of time from development of duodenal obstruction to death was 4.8 ± 2.1 months (range 0.5-60 months). Average survival time from diagnosis to death was 16.6 ± 5.6 months (range 4.5-58 months). CONCLUSION: Thirty-eight percent of patients with unresectable pancreatic head adenocarcinoma and metal biliary stents who receive chemotherapy and/or radiation therapy eventually develop symptomatic duodenal obstruction requiring duodenal stent or surgical bypass. This rate of duodenal obstruction is nearly twice that of previous reports using older oncologic therapy and will likely increase as patients survive longer with advances in medical therapy for pancreatic cancer.
Authors: Thierry Conroy; Françoise Desseigne; Marc Ychou; Olivier Bouché; Rosine Guimbaud; Yves Bécouarn; Antoine Adenis; Jean-Luc Raoul; Sophie Gourgou-Bourgade; Christelle de la Fouchardière; Jaafar Bennouna; Jean-Baptiste Bachet; Faiza Khemissa-Akouz; Denis Péré-Vergé; Catherine Delbaldo; Eric Assenat; Bruno Chauffert; Pierre Michel; Christine Montoto-Grillot; Michel Ducreux Journal: N Engl J Med Date: 2011-05-12 Impact factor: 91.245
Authors: K D Lillemoe; J L Cameron; J M Hardacre; T A Sohn; P K Sauter; J Coleman; H A Pitt; C J Yeo Journal: Ann Surg Date: 1999-09 Impact factor: 12.969
Authors: Suzanne M Jeurnink; Ewout W Steyerberg; Jeanin E van Hooft; Casper H J van Eijck; Matthijs P Schwartz; Frank P Vleggaar; Ernst J Kuipers; Peter D Siersema Journal: Gastrointest Endosc Date: 2009-12-08 Impact factor: 9.427
Authors: Jeanin E van Hooft; Madeleen J Uitdehaag; Marco J Bruno; Robin Timmer; Peter D Siersema; Marcel G W Dijkgraaf; Paul Fockens Journal: Gastrointest Endosc Date: 2009-01-18 Impact factor: 9.427
Authors: Anna Fábián; Renáta Bor; Noémi Gede; Péter Bacsur; Dániel Pécsi; Péter Hegyi; Barbara Tóth; Zsolt Szakács; Áron Vincze; István Ruzsics; Zoltán Rakonczay; Bálint Erőss; Róbert Sepp; Zoltán Szepes Journal: Clin Transl Gastroenterol Date: 2020-04 Impact factor: 4.396